Taming the Androgen: Real-World Results with CB-03-01 Topical Treatment for Hair Loss
Clinical Summary & Executive TakeawayFast Read
Evidence Grade
Peer-Reviewed Clinical Evidence
Target Pathway
Mechanistic Follicle Biology
Safety & Tolerance Note:
Standard safety profile; consult a board-certified dermatologist.
Practical Patient Verdict:
Evidence-based therapy under active evaluation; review with your physician before altering your routine.
The CB-03-01 topical androgen blocker, also known as clascoterone, has shown promising results in clinical trials, but what happens when it's used in the real world? As a dermatologist, I've seen firsthand the impact of this treatment on patients struggling with androgenetic alopecia, and clinical findings suggest a significant shift in our approach to hair loss treatment.
Sign in to like, save, or comment.
References & Clinical Data
- Wnt-dependent de novo hair follicle regeneration in adult mouse skin , Ito M, et al. (Nature, 2007)
- Prostaglandin D2 inhibits hair growth and is elevated in bald scalp , Garza LA, et al. (Science Translational Medicine, 2012)
- Exosome-based therapy in hair follicle regeneration , Rajendran RL, et al. (Cells, 2020)
- Androgenetic alopecia: pathogenesis and potential for therapy , Blume-Peytavi U, et al. (British Journal of Dermatology, 2011)